Metropolis Healthcare Limited — Investor Meet, 19-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Metropolis Healthcare reported strong Q4 FY26 Group revenue of ₹425 Cr (+23% YoY) and EBITDA of ₹108 Cr (25.4% margin, +71% YoY). Organic revenue grew 14.7%, driven by 9.3% patient volume growth. FY26 organic EBITDA margin expanded 140 bps to 25.9%. Management projects a 14-15% revenue CAGR over the next 3 years, targeting sustainable group EBITDA margins of 27-28%. Key growth drivers include specialty diagnostics, genomics, and digital channels now contributing 25% of revenue. Plans include 100 mini hubs and 1,500 new collection centers, aiming to boost network productivity by 20% over three years. Sentiment is confident, emphasizing operational efficiency and strategic investments.